The coronavirus disease 2019 (COVID-19), caused by the novel coronavirus, SARS-CoV-2,
affects tissues from different body systems but mostly the respiratory system, and the
damage evoked in the lungs may occasionally result in severe respiratory complications
and eventually lead to death. Studies of human respiratory infections have been limited
by the scarcity of functional models that mimic in vivo physiology and pathophysiology.
In the last decades, organoid models have emerged as potential research tools due to the
possibility of reproducing in vivo tissue in culture. Despite being studied for over one
year, there is still no effective treatment against COVID-19, and investigations using
pulmonary tissue and possible therapeutics are still very limited. Thus, human lung
organoids can provide robust support to simulate SARS-CoV-2 infection and replication
and aid in a better understanding of their effects in human tissue. The present review
describes methodological aspects of different protocols to develop airway and alveoli
organoids, which have a promising perspective to further investigate COVID-19.